.gif)
The booming biotech industry in the Middle East has grown to about $32 billion in 2020 and continues to rise. Globally, the middle eastern biopharmaceuticals market is expected to experience its highest growth ever from 19 to 29 Billion USD from 2021 to 2026.
Here are 20 of the top biotech companies in the Middle East:
President & Chief Executive Officer - David Baram
Located in Ness Ziona, Israel, Emendo Biotherapeutics develops novel gene-editing tools designed for genetic disorders. Using protein engineering, the company resolves bottlenecks in gene therapy, enabling doctors to look into treating disorders that are currently considered untreatable.
President & Chief Executive Officer - Joe H.
Located in Dubai, UAE NewBridge Pharmaceuticals develops therapeutics and medical devices designed to treat diabetes, cancer, metabolic disorders, and cardiovascular diseases.
Chief Executive Officer - Amir Farshchi
Located in Tehran, Iran, AryoGen Pharmed manufactures and provides biopharmaceutical products to the national and international market. Some of its offerings are AryoSeven™ which is used for the treatment of blood disorders, Zytux™ which is used for the treatment of Non-Hodgkin’s Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL),and Altebrel™ - which is used for the treatment of Psoriasis-Arthritis, Axial Spondyloarthritis.
President & Chief Executive Officer - Dror Bashan
Located in Carmiel, Israel, Protalix BioTherapeutics develops recombinant therapeutic proteins using its proprietary ProCellEx protein expression system. The company's products are used to treat Gaucher diseases, Fabry disease, and cystic fibrosis.
Chief Executive Officer - Asaf Danziger
Based in Haifa, Israel with offices all over the world, Novocure uses its innovative therapy, Tumor Treating Fields, to treat critical tumors. Their products have been approved to treat glioblastoma and malignant pleural mesothelioma in certain countries.
Chief Executive Officer - Eyal Shamir
Located in Caesarea, Israel, IceCure Medical uses its technology to perform cryoablation which is a treatment to kill cancer cells using liquid nitrogen. The liquid nitrogen is pumped directly into the tumor to freeze its tissue and ultimately destroy it. IceCure medical uses this technology for the treatment of benign and malignant breast tumors, renal, lung, and bone cancer.
Chief Executive Officer - Madhukar Tanna
Located in Dubai, UAE Pharmax manufactures affordable, high-quality medications in the MENA (Middle East & North Africa) region. These medications are used in urology, cardiovascular, gastroenterology, and other fields.
Chief Executive Officer - Amotz Shemi
Located in Modi’in, Israel, Silenseed develops RNA interference (RNAi)-based drugs and delivery systems intended to treat malignant solid tumors.
Chief Executive Officer - Shalina Clifford
Located in Dubai, UAE Shalina Healthcare manufactures and distributes affordable healthcare products that treat diseases in the cardiovascular, oncology, gynecology, and respiratory fields.
Chief Financial Officer & Chief Executive Officer - Oz Adler
Located in Israel, SciSparc creates assets and technologies based on cannabinoid pharmaceuticals. The company is currently engaged in drug development programs for the treatment of Tourette's syndrome, sleep apnea, pain management, autism, and epilepsy.
Chief Executive Officer & Chief Technology Officer - Michal Amit
Located in Haifa, Israel, Accellta creates and offers stem cell technologies for cost-effectively mass-producing human embryonic and induced pluripotent stem cells. These stem cells are used for drug discovery and regenerative medicine.
Chief Financial Officer - Sam Backenroth
Located in Modi’in, Israel, VBL Therapeutics is working on the development and commercialization of first-in-class treatments for cancer. Their lead product VB-111 is being developed to treat recurrent glioblastoma.
Chief Executive Officer - Phil Serlin
Located in Modi’in, Israel, BioLineRx creates therapeutics with a focus on oncology. Currently, its pipeline consists of two candidates in the clinical stage — Motixafortide and AGI-134. The former is a peptide used for treating pancreatic cancer and the latter is an immuno-oncology agent used to treat solid tumors.
Chief Executive Officer - Yaron Pereg
Located in Jerusalem, Israel, KAHR develops drugs designed to overcome the camouflaging ability of cancer cells to evade recognition by the immune system. Using their multifunctional immuno-recruitment protein (MIRP) technology, KAHR elicits an immune response by tagging these cancer cells and making them visible.
Chief Executive Officer - Gili Hart
Located in Jerusalem, Israel, Splisense develops drug candidates using antisense oligonucleotides intended to fix splicing mutations involved with genetic diseases. This helps clinicians treat cystic fibrosis, Chronic obstructive pulmonary disease (COPD), Primary ciliary dyskinesia (PCD), and other genetic diseases. .
Founder - Dr. Michael Har-Noy
Located in Jerusalem, Israel, Immunovative Therapies develops drugs that incorporate immune cells. These drugs are intended to modulate the immune system to target cancer and other infectious diseases.
Founder & Chief Scientific Officer - Prof. Yechezkel Barenholz
Located in Jerusalem, Israel, LipoCure develops liposomal nano-drugs used for treating cancer, inflammation, and palmar-plantar erythrodysesthesia.
Chief Executive Officer - Fabian Tenenbaum
Located in Jerusalem, Israel, Nectin Therapeutics develops antibodies designed to treat hematological and solid malignancies. These antibodies are specific to the nectin receptors and ligands that play a crucial role when identifying mechanisms for cancer immunotherapy.
Chief Executive Officer - Amir London
Located in Negev, Israel, Kamada develops plasma-derived therapeutics using their proprietary protein purification technology. Its two leading products are GLASSIA®, the first liquid, ready-to-use, intravenous plasma-derived Alpha-1 Antitrypsin (AAT), and KamRAB, a rabies immune globulin (Human) for Post-Exposure Prophylaxis against rabies infection. Both of these products have been approved by the U.S. Food and Drug Administration.
Chief Executive Officer - Shai Yarkoni
Located in Kfar Saba, Israel, Cellect develops regenerative medicine technology by enabling mass enrichment of stem cells as a raw material for any regenerative treatments.
Subscribe to us on YouTube and follow us on LinkedIn and Twitter to learn more about noteworthy trends, breakthroughs, and all kinds of essential news for the bioeconomy workforce.
